Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | HRH1 | P35367 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | PTPRA | P18433 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6196923 | 0.89 | SMN1; SMN2 (0.68) | CYP1A2SMN1; SMN2CYP2C19HRH1TDP1 | |
| SCHEMBL29499090 | 0.84 | SMN1; SMN2 (0.62) | CYP1A2SMN1; SMN2CYP2C19HRH1TDP1 | |
| SCHEMBL333243 | 0.84 | SMN1; SMN2 (0.62) | CYP1A2SMN1; SMN2CYP2C19HRH1TDP1 | |
| Hydrochloric Acid SCHEMBL4174816 | 0.82 | SMN1; SMN2 (0.60) | CYP1A2SMN1; SMN2CYP2C19HRH1TDP1 | |
| SCHEMBL403460 | 0.82 | CYP1A2 (0.56) | CYP1A2SMN1; SMN2CYP2C19HRH1TDP1 | |
| Hydrochloric Acid SCHEMBL28672925 | 0.82 | SMN1; SMN2 (0.60) | CYP1A2SMN1; SMN2CYP2C19HRH1TDP1 | |
| SCHEMBL626826 | 0.82 | HRH1 (0.57) | CYP1A2SMN1; SMN2CYP2C19HRH1TDP1 | |
| SCHEMBL5493166 | 0.82 | SMN1; SMN2 (0.56) | CYP1A2SMN1; SMN2CYP2C19HRH1TDP1 | |
| Lithium Ion SCHEMBL28463950 | 0.82 | CYP1A2 (0.56) | CYP1A2SMN1; SMN2CYP2C19HRH1TDP1 | |
| SCHEMBL2722250 | 0.82 | ALDH1A1 (0.57) | CYP1A2SMN1; SMN2CYP2C19HRH1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0604368-B1 | Anti retroviral hydrazine derivatives | CIBA GEIGY AG (CH) | 1996-09-18 | — | — | EP | disclosed |
| CN-1093701-A | Antiretroviral hydrazine derivative | CIBA GEIGY AG (CH) | 1994-10-19 | — | — | CN | disclosed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | CYP1A2 1864/4885SMN1; SMN2 1200/4885CYP2C19 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.